Today, the Epilepsy Foundation and a diverse group of more than 90 advocacy organizations submitted a letter to the House and Senate Judiciary Committees urging Congress to maintain a strong and secure patent system that encourages investments in innovative treatments and devices as it considers comprehensive patent reform.
Together, our organizations represent millions of individuals waiting for the next breakthrough treatment, and hopefully, cure. Without strong patents, many innovative ideas will not make it from the lab to a patient suffering from a debilitating disease or condition. Simply stated, intellectual property protects innovation and attracts the investors needed to sustain the long and risky process of bringing new treatments and devices to market.
The Epilepsy Foundation is concerned about recent abusive practices to invalidate these critically important patents through the U.S. Patent and Trademark Office’s Inter Partes Review process. If this issue is not addressed by Congress, we at the Foundation worry there will be a chilling effect on the drug pipeline and less investments in the promising field of epilepsy devices.
As a parent of a child living with epilepsy, I know just how important innovation is to improving the quality of life for individuals living with seizures. And as the president and CEO of the Epilepsy Foundation, I am proud that we place an exceptional focus on advancing new therapies in a timeframe that matters for all people with epilepsy today. Strong patent protectionscan accelerate the discovery and development of new products, devices, and therapies that individuals with epilepsyand many other complex, chronic conditions deserve to help them live their lives to the fullest potential.
In an environment where research funding is hard to secure and results take years to achieve, we must ensure that we can rely on the patent system to protect the promise of future medical breakthroughs. To view the letter to the House and Senate Judiciary Committees, please click here.
Philip M. Gattone, M.Ed.
President & CEO